Luye Pharma Group Ltd. (02186) announced that on 26 January 2026, Shenzhen Luye, NJ Xinshi, Nanjing Xinan, Ningbo Cinda, and Nanjing Luye entered into agreements for a capital injection totaling RMB285 million by Nanjing Xinan and Ningbo Cinda. Upon completion, Nanjing Luye’s shareholding structure will change to: 70.01% held by Shenzhen Luye, 23.34% by NJ Xinshi, 4.32% by Nanjing Xinan, and 2.33% by Ningbo Cinda.

According to the announcement, the transaction constitutes a deemed disposal under Rule 14.29 of the Listing Rules and also involves put options and call options over Nanjing Luye equity interests. The put options granted to the new investors are classified as discloseable transactions under Chapter 14, while the call options do not constitute notifiable transactions at this stage. As the parties involved are connected persons at the subsidiary level, the transaction is recognized as a connected transaction, subject to announcement requirements but exempt from circular and shareholder approval under Rule 14A.101. The capital will be used to repay existing indebtedness or operating liabilities, with Nanjing Luye remaining a subsidiary of Luye Pharma Group after the injection. The company highlights that this arrangement strengthens Nanjing Luye’s capital structure and provides additional institutional capital support for its oncology-focused operations.